Organon Q1 2024 Adj EPS $1.22 Beats $0.93 Estimate, Sales $1.622B Beat $1.563B Estimate
Portfolio Pulse from Benzinga Newsdesk
Organon (NYSE:OGN) reported Q1 2024 adjusted EPS of $1.22, surpassing the $0.93 estimate, and sales of $1.622B, exceeding the $1.563B estimate. This represents a 12.96% increase in EPS and a 5.46% increase in sales from the same period last year.
May 02, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Organon reported a significant beat on both EPS and sales estimates for Q1 2024, with EPS at $1.22 against a $0.93 estimate and sales of $1.622B against a $1.563B estimate.
Beating both EPS and sales estimates by a significant margin indicates strong financial performance and operational efficiency. This outperformance, especially in a year-over-year comparison, is likely to positively influence investor sentiment and potentially lead to a short-term uptick in OGN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100